EPIRUS Biopharmaceuticals and mAbxience Sign Latin America

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EPIRUS Biopharmaceuticals and mAbxience Sign Latin America Distribution Deal for Infliximab Biosimilar, BOW015

BOSTON, May 14, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS ) and mAbxience , a biopharmaceutical company specialized in research, development and manufacturing of biosimilars, entered into a development and future distribution deal for EPIRUS' lead program, BOW015 (infliximab, reference biologic Remicade®), for Latin American markets, including Argentina, Chile, Ecuador, Paraguay, Uruguay and Venezuela.

mAbxience is a wholly-owned subsidiary of CHEMO Group , a well-established global healthcare corporation. CHEMO Group generates over $1 billion in annual revenues with 5,000 professionals across 40 countries.

Leveraging the CHEMO Group's infrastructure, mAbxience will be responsible for regulatory submissions, using BOW015's existing data package, and eventual commercialization in these select Latin American markets. 

"We are pleased to work with a strong regional partner to register and commercialize our infliximab biosimilar," stated Amit Munshi, president and chief executive officer, EPIRUS Biopharmaceuticals. "We are committed to improving patient access to biosimilars globally and believe mAbxience has the right focus and infrastructure in these markets to advance this important medicine."

"This is an exciting development for both companies. We are confident in our ability to execute and advance BOW015, given the high quality of the existing data package and our expertise within these regions," said Carlos Bañado, chief executive officer, mAbxience.  

About mAbxience

mAbxience is a global fully integrated biopharmaceutical company specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas. mAbxience is acting worldwide, creating a broad and balanced presence in all major pharmaceutical markets to address global opportunities and customers' needs, with full-line research and manufacturing capabilities and highly qualified professionals worldwide. mAbxience is a wholly-owned subsidiary of CHEMO Group, a well-established Spanish-based global healthcare corporation. For more information visit mAbxience website at http://www.mabxience.com .  

About EPIRUS Biopharmaceuticals

EPIRUS Biopharmaceuticals (Nasdaq: EPRS ) is a global biosimilar company focused on improving patient access to important medicines.  EPIRUS' operationally synergistic pipeline of biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab). The reference products for these candidates -- Remicade®, Humira® and Actemra®, respectively -- together generated $23 billion in global sales for 2014, according to EvaluatePharma®.  EPIRUS has developed distinct strategies to access its targeted markets with the goal to build a profitable and sustainable biosimilar business. For more information visit EPIRUS' website at www.epirusbiopharma.com .

Remicade is a registered trademark of Johnson and Johnson ( www.jnj.com )

Humira is a registered trademark of AbbVie ( www.abbvie.com )

Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group ( www.gene.com )

Forward-Looking Statements

Various statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this document, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to EPIRUS or its management may identify forward-looking statements. EPIRUS cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by EPIRUS to secure and maintain relationships with collaborators and single-source contract manufacturers; risks relating to clinical trials; risks relating to the commercialization, if any, of EPIRUS' proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; risks related to the loss of any of EPIRUS' key management personnel; risks that EPIRUS may lack the financial resources and access to capital to fund proposed operations and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of EPIRUS' annual report on Form 10-K for the fiscal year ended December 31, 2014 which is on file with the SEC and available on the SEC's website at www.sec.gov . In addition to the risks described above and in EPIRUS' annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect EPIRUS' results. There can be no assurance that the actual results or developments anticipated by EPIRUS will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, EPIRUS. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to EPIRUS or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. EPIRUS cautions investors not to rely too heavily on the forward-looking statements EPIRUS makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and EPIRUS undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Jennifer Almond, EPIRUS Biopharmaceuticals, Inc. +1-617-606-3288 Lara Recuero, CHEMO Group +34 91 771 15 00

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 45

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 106

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 52

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 56

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 111

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 77

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 148

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 45

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 83

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading

Top 5 Most Recently Viewed Articles

Tevogen Bio Achieves Nasdaq Compliance and Future Prospects

Updated Category News Views 107

Tevogen Bio Regains Compliance with Nasdaq Listing Standards Tevogen Bio Holdings Inc. (NASDAQ: TVGN), a clinical-stage company specializing in immunotherapy, recently made headlines with its announcement of regained compliance with Nasdaq's listing standards. This pivotal moment for Tevogen showcases its dedication to maintaining a strong presence in the biotech...

Continue Reading
aTyr Pharma Investors: Join the Class Action Opportunity

Updated Category News Views 270

Understanding Your Rights as a Shareholder of aTyr Pharma Investors in aTyr Pharma, Inc. (NASDAQ: ATYR) are currently faced with a significant opportunity as a class action lawsuit has been initiated. This legal action is directed towards addressing serious concerns regarding the company's disclosures and conduct during a specific timeframe when many shareholders acquired...

Continue Reading
Chinafy and Lianwei Unite for Enhanced Web Solutions

Updated Category News Views 260

Chinafy and Lianwei Unveil Strategic Collaboration In an exciting development, Chinafy, a renowned cross-border web optimization platform, has announced a strategic partnership with Lianwei, a reputable provider of security and compliance consulting services. This collaboration marks the beginning of a new chapter in ensuring efficient web performance and regulatory...

Continue Reading
Insights on Octopus AIM VCT 2 plc's Current Net Asset Value

Updated Category News Views 107

Understanding the Current Net Asset Value of Octopus AIM VCT 2 plc Octopus AIM VCT 2 plc is a venture capital trust that has recently disclosed some important financial metrics regarding its net asset value (NAV). Knowing the NAV is crucial for investors as it represents the value of the company's assets minus liabilities, particularly helpful for assessing the worth of...

Continue Reading
FTAI Aviation: Unpacking Market Sentiment and Trends

Updated Category News Views 195

Understanding the Current Market Sentiment of FTAI Aviation In the realm of investments, the behavior of high-capital investors, often referred to as "whales," provides insightful indicators of market trends. Recently, these investors have taken a notably bearish stance on FTAI Aviation. Upon analyzing the options trading history for FTAI Aviation, there have been a total...

Continue Reading